Terumo Europe was established in 1971 as the European, Middle East, and African headquarters of Japan-based Terumo Corporation, which was founded in 1921 by Dr. Kitasaburo Kitasato and a group of medical scientists. Today, Terumo Europe serves as a core player in the EMEA healthcare market, providing best-in-class medical products and services across 23 locations with 1,411 associates. The company achieved €839.4 million in net sales in fiscal year 2023, conducting business locally while pursuing a unified regional strategy. Terumo Europe specializes in minimally invasive medical technologies that enable healthcare professionals to treat serious cardiovascular conditions through interventional procedures rather than open surgery, reducing patient trauma and recovery times.
The company operates across multiple medical fields including Interventional Cardiology, Interventional Oncology, Peripheral Intervention, Cardiovascular Surgery, Injection, Infusion Therapy, and Diabetes Care. Their portfolio encompasses devices for diagnosis and treatment of coronary artery disease, peripheral artery disease, and other vascular conditions. Terumo Europe is recognized for manufacturing excellence, with their Heverlee, Belgium facility being named a "Factory of the Future." Guided by core values of Respect, Integrity, Care, and Quality, the company is committed to contributing to society through healthcare innovation, listening sincerely to patient needs, and working closely with healthcare professionals to advance patient care and enhance quality of life.